Connect with us

China

#COVID-19 - EU and industry to fund more research through #InnovativeMedicinesInitiative

SHARE:

Published

6 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Innovative Medicines Initiative (IMI), a public-private partnership between the European Commission and the pharmaceutical industry, has today launched a fast-track call for research proposals to develop treatments and diagnostics in response to the COVID-19 outbreak.

Up to €45 million of the funding will come from Horizon 2020, the EU research and innovation programme, and a commitment of a similar scale is expected from the pharmaceutical industry so that the total investment could reach up to €90m. Innovation, Research, Culture, Education and Youth Commissioner Mariya Gabriel said: “I welcome the rapid response of IMI to the Coronavirus outbreak. This collaboration between the public and the private sectors brings their expertise and resources together in our fight against the Coronavirus outbreak. This will help speed up the development of treatments and diagnostics in face of this global emergency and increase our preparedness for future outbreaks.”

This call is part of the co-ordinated EU response to the public health threat of COVID-19 and complements the emergency research funding already mobilized recently under Horizon 2020. You can find more information about the IMI call here, and the EU research actions on COVID-19 here.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending